



---

**Composition:**

Oxymetazoline            0.025%w/v

Sorbitol                    2%w/v

**Pharmacokinetic properties:**

Sorbitol is poorly absorbed from the gastrointestinal tract after oral or rectal use. It is metabolised mainly in the liver, to fructose, a reaction catalysed by the enzyme sorbitol dehydrogenase. Some sorbitol may be converted directly to glucose by the enzyme aldose reductase.

**Mechanism of Action**

Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion.

Sorbitol prevents dehydration thus enhances moisturisation of nasal mucosa.

**Other pharmacodynamic properties:**

Oxymetazoline a adrenergic alpha-agonists, direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis.

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements.

**Indication:**

Sinarest Nasal spray is indicated for:

- Relief of nasal congestion due to a cold, upper respiratory allergies or sinusitis.

**Contraindication:**

*We Impart Health to Life*

The use of Sinarest Nasal spray is contraindicated in patients with known hypersensitivity to its ingredient.

**Drug Interaction:**

Clinically significant drug interactions may occur on concomitant administration of Sinarest Nasal spray with monoamine oxidase inhibitors, tricyclic antidepressants, b-adrenergic agents, methyldopa, reserpine and veratrum alkaloids.

**Adverse effects:**

Sinarest Nasal spray may occasionally cause local stinging or burning sensation, sneezing, and dryness of the mouth and throat. Prolonged use may cause rebound congestion and drug induced rhinitis.

**Warnings and Precautions:**

- Sinarest Nasal spray should be administered with caution in patients with hypertension, coronary artery disease, hyperthyroidism or diabetes mellitus.
- As with formulations, the use of the same packing of SINAREST Nasal spray by more than one person may spread infection.

**Use in special population:**

1. **Pediatric:** The safety of use of SINAREST Nasal Spray in children has not been established.
2. **Geriatric:** The safety of use of SINAREST Nasal Spray in elderly patients has not been established.
3. **Liver impairment:** The safety of use of SINAREST Nasal Spray has not been established.
4. **Renal failure:** The safety of use of SINAREST Nasal Spray has not been established.
5. **Pregnancy and lactation:** The safety of use of SINAREST Nasal Spray in pregnancy and lactation has not been established. Therefore, use only when clearly indicated.

**Dosage:**

As directed by physician.

**Presentation:**

Sinarest Nasal spray is available in 10 ml bottle with calibrated dropper

**Storage and handling:**

Store in cool and dry place.



*We Impart Health to Life*